31-45 of 388
Understanding the Effect of Targeting IL-17A/F in Psoriatic Arthritis
Practical Dermatology: IL-17 Journal ClubUnderstanding the Effect of Targeting IL-17A/F in Psoriatic Arthritis
Neal Bhatia, MD
Naiem T. Issa, MD, PhD, FAAD
Practical Strategies for Improving Adherence in Psoriasis Care
On the Frontlines of PsoriasisPractical Strategies for Improving Adherence in Psoriasis Care
Ryan Quigley
Steven R. Feldman, MD, PhD
JAK Inhibitors in Psoriatic Arthritis: Reassessing Safety in the Real World
Living RheumJAK Inhibitors in Psoriatic Arthritis: Reassessing Safety in the Real World
Shared CD8+ T Cell Clones Link Skin and Joint Inflammation in Psoriatic Arthritis
Living RheumShared CD8+ T Cell Clones Link Skin and Joint Inflammation in Psoriatic Arthritis
Validating hf-PGA for Hand and Foot Psoriasis Severity in Adults
DermConsultValidating hf-PGA for Hand and Foot Psoriasis Severity in Adults
IL-17A Inhibition and Neuroendocrine Signaling in Psoriasis
DermConsultIL-17A Inhibition and Neuroendocrine Signaling in Psoriasis
- advertisement
Ryan Quigley
IL-17A Inhibition and the Stress Response in Psoriasis
AudioAbstractsIL-17A Inhibition and the Stress Response in Psoriasis
Ryan Quigley
Addressing Diagnostic Gaps in Psoriasis for Skin of Color
DermConsultAddressing Diagnostic Gaps in Psoriasis for Skin of Color
Megan R Hauptman, MD
Rethinking Quality-of-Life Tools for Psoriasis Patients with Skin of Color
DermConsultRethinking Quality-of-Life Tools for Psoriasis Patients with Skin of Color
Megan R Hauptman, MD
How Can We Make Psoriasis Research More Equitable?
DermConsultHow Can We Make Psoriasis Research More Equitable?
Megan R Hauptman, MD
Optimizing Narrowband UVB Therapy for Psoriasis in Skin of Color
On the Frontlines of PsoriasisOptimizing Narrowband UVB Therapy for Psoriasis in Skin of Color
Ryan Quigley
Megan R Hauptman, MD
- advertisement
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
AudioAbstractsImproving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
Ryan Quigley
Cosibelimab Delivers Durable Responses in Advanced CSCC
Project Oncology®Cosibelimab Delivers Durable Responses in Advanced CSCC
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Project Oncology®Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
